Study of Timing Effects of Deep Brain Stimulation in Adults with Treatment-Resistant Obsessive-Compulsive Disorder Targeting Anterior Limb of Internal Capsule and Nucleus Accumbens

What this Trial Is About

Researchers are evaluating deep brain stimulation DBS targeting the anterior limb of internal capsule and nucleus accumbens ALIC-NAc in patients with treatment-refractory obsessive-compulsive disorder OCD. The study aims to find out whether the timing of DBS activationat 1, 2, or 3 months after surgeryaffects the improvement of OCD symptoms measured by Y-BOCS scores. This multicenter, randomized, open-label trial involves adults who have not responded to standard medications and therapy. Participants will undergo surgery to implant a neurostimulation device in the brain. They will be randomly assigned to one of three groups receiving DBS activation at approximately 30, 60, or 90 days after surgery. Each group includes 20 patients. After activation, participants will be regularly assessed over a six-month follow-up period to compare symptom improvements based on activation timing. During the study, participants will attend scheduled clinical visits for evaluations including OCD symptom scores, depression and anxiety ratings, and quality of life assessments. The main measurement is the difference in OCD symptom improvement three months after DBS activation. Secondary measures include changes in clinical global impression, depression, anxiety, and health survey scores at one, two, and three months post-activation. Safety and suitability assessments will also be conducted throughout the trial, which is expected to complete by March 2027.

Efficacy and Influencing Factors of ALIC-NAc Deep Brain Stimulation in Treatment-Refractory Obsessive-Compulsive Disorder